Beyond Air preannounces Q3 revenue of $2.3M, up 30% sequentially and 27% YoY; reaffirms CY2026/CY2027 guidance

Beyond Air, Inc.

Preliminary unaudited revenue of ~$2.3 million for the quarter ended September 30, 2026, the highest quarterly revenue reported to date.
Revenue rose about 30% versus the quarter ended June 30, 2026 and 27% versus the same quarter last year on LungFit PH adoption.
Guidance reaffirmed: $8 million for CY2026 (excludes second-generation LungFit PH) and $16-$18 million for CY2027 (includes second-gen, pending FDA approval).
Second-generation LungFit PH remains under FDA review via an ongoing PMA supplement; adding transport capability would make Beyond Air a single-source nitric oxide provider.
CEO Robert Goodman credits the enhanced commercial execution strategy; full Q3 results will be reported in November 2026.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.